Comparative Pharmacology
Head-to-head clinical analysis: DOXY LEMMON versus PANMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXY LEMMON versus PANMYCIN.
DOXY-LEMMON vs PANMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A site.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg orally or intravenously once daily.
250-500 mg PO q6h or 500 mg to 1 g IV q6h; maximum 4 g/day
None Documented
None Documented
Terminal elimination half-life: 18-22 hours (mean ~20 hours) in adults with normal renal function. Clinically, this supports twice-daily dosing; prolonged in severe renal impairment (up to 40-60 hours) or hepatic impairment.
Terminal elimination half-life is 6-8 hours in patients with normal renal function. Half-life is significantly prolonged (up to 80 hours) in anuria, requiring dose adjustment.
Renal (approx. 40% as unchanged drug via glomerular filtration), biliary/fecal (approx. 60% as active and inactive metabolites, with significant enterohepatic recycling). Dose adjustment not required in mild renal impairment, but caution in severe hepatic dysfunction.
Primarily renal excretion of unchanged drug via glomerular filtration; 80-90% recovered in urine within 24 hours. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic